deltatrials
Recruiting PHASE3 INTERVENTIONAL 12-arm NCT03643276

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

Sponsor: Deutsche Krebshilfe e.V., Bonn (Germany)

Conditions Acute Lymphoblastic Leukemia, Pediatric
Interventions 6-Mercaptopurine Blinatumomab Bortezomib Cyclophosphamide Cytarabine Daunorubicin Dexamethasone Doxorubicin Erwinase Etoposide Fludarabine Phosphate Ifosfamide Methotrexate Myocet Pegaspargase Prednisolone Tioguanin Vincristine Vindesine
Updated 14 times since 2018 Last updated: Apr 3, 2025 Started: Jul 15, 2018 Primary completion: Jul 14, 2028 Completion: Jul 14, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Acute Lymphoblastic Leukemia, Pediatric, this trial is actively recruiting participants. The trial is conducted by Deutsche Krebshilfe e.V., Bonn (Germany) and has accumulated 14 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Sep 2018 – ~Feb 2019 · 5 months · monthly snapshot~Feb 2019 – ~Jun 2019 · 4 months · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Feb 2020 · 7 months · monthly snapshot~Feb 2020 – ~Nov 2020 · 9 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2022 · 15 months · monthly snapshot~Dec 2022 – ~Dec 2023 · 12 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Recruiting PHASE3

  2. May 2025 — Sep 2025 [monthly]

    Recruiting PHASE3

  3. Sep 2024 — May 2025 [monthly]

    Recruiting PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  5. Dec 2023 — Jul 2024 [monthly]

    Recruiting PHASE3

▶ Show 9 earlier versions

  1. Dec 2022 — Dec 2023 [monthly]

    Recruiting PHASE3

  2. Sep 2021 — Dec 2022 [monthly]

    Recruiting PHASE3

  3. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  4. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  5. Feb 2020 — Nov 2020 [monthly]

    Recruiting PHASE3

  6. Jul 2019 — Feb 2020 [monthly]

    Recruiting PHASE3

  7. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE3

  8. Feb 2019 — Jun 2019 [monthly]

    Recruiting PHASE3

  9. Sep 2018 — Feb 2019 [monthly]

    Recruiting PHASE3

    First recorded

Jul 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Deutsche Krebshilfe e.V., Bonn (Germany)
  • Martin Schrappe
Data source: University Hospital Schleswig-Holstein

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Aarau, Switzerland , Ancona, Italy , Augsburg, Germany , Banská Bystrica, Slovakia , Bari, Italy , Basel, Switzerland , Beersheba, Israel , Bellinzona, Switzerland , Bergamo, Italy and 98 more locations